.Background The pharmacological stimulation of GLP-1 receptors is associated with an increase in heart rate. A pooled analysis of patient-level data from phase III trials with albiglutide revealed a significant increase in the risk of atrial fibrillation. Aim of the present meta-analysis is to summarize all available evidence on the effects of individual GLP-1 receptor agonists (RA), and of the whole class, on the incidence of atrial fibrillation. Methods A Medline search for GLP-1 RA (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥12 weeks, enrolling patients with type 2 diabetes and comparing a GLP-1 RA with placebo or any other non-GLP-1 RA drug. Results Of the 113 trials fulfilling the inclusion criteria, 19 did not report information on atrial fibrillation, whereas 63 reported zero events in all treatment groups. In the remainingRA and comparator arms, respectively, 55.3% women, with a mean age of 57.0 ± 3.8 years), treatment with GLP-1 RA was not associated with a significant increase in the incidence of atrial fibrillation [Mantel–Haenszel OR (95% CI) 0.87 (0.71–1.05), p = 0.15]. Conclusions In conclusion, available data suggest that GLP-1 RA is not associated with atrial fibrillation, with the only possible exception of albiglutide. Newly onset atrial fibrillation deserves to be investigated as an event of special interest in future trials with GLP-1 RA. trials (enrolling 17,966 and 15,305 patients in GLP-1

Glucagon-like peptide-1 receptor agonists and atrial fibrillation. a systematic review and meta-analysis of randomised controlled trials / Monami, M; Nreu, B; Scatena, A; Giannini, S; Andreozzi, F; Sesti, G; Mannucci, E.. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - 40:11(2017), pp. 1251-1258. [10.1007/s40618-017-0698-7]

Glucagon-like peptide-1 receptor agonists and atrial fibrillation. a systematic review and meta-analysis of randomised controlled trials

Sesti G
Penultimo
Writing – Review & Editing
;
2017

Abstract

.Background The pharmacological stimulation of GLP-1 receptors is associated with an increase in heart rate. A pooled analysis of patient-level data from phase III trials with albiglutide revealed a significant increase in the risk of atrial fibrillation. Aim of the present meta-analysis is to summarize all available evidence on the effects of individual GLP-1 receptor agonists (RA), and of the whole class, on the incidence of atrial fibrillation. Methods A Medline search for GLP-1 RA (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration ≥12 weeks, enrolling patients with type 2 diabetes and comparing a GLP-1 RA with placebo or any other non-GLP-1 RA drug. Results Of the 113 trials fulfilling the inclusion criteria, 19 did not report information on atrial fibrillation, whereas 63 reported zero events in all treatment groups. In the remainingRA and comparator arms, respectively, 55.3% women, with a mean age of 57.0 ± 3.8 years), treatment with GLP-1 RA was not associated with a significant increase in the incidence of atrial fibrillation [Mantel–Haenszel OR (95% CI) 0.87 (0.71–1.05), p = 0.15]. Conclusions In conclusion, available data suggest that GLP-1 RA is not associated with atrial fibrillation, with the only possible exception of albiglutide. Newly onset atrial fibrillation deserves to be investigated as an event of special interest in future trials with GLP-1 RA. trials (enrolling 17,966 and 15,305 patients in GLP-1
2017
meta-analysis; GLP-1 receptor agonists; atrial fbrillation
01 Pubblicazione su rivista::01a Articolo in rivista
Glucagon-like peptide-1 receptor agonists and atrial fibrillation. a systematic review and meta-analysis of randomised controlled trials / Monami, M; Nreu, B; Scatena, A; Giannini, S; Andreozzi, F; Sesti, G; Mannucci, E.. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - 40:11(2017), pp. 1251-1258. [10.1007/s40618-017-0698-7]
File allegati a questo prodotto
File Dimensione Formato  
Monami_Glucagon-like_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 504.08 kB
Formato Adobe PDF
504.08 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1312767
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 46
social impact